Adage Capital Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Adage Capital Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.1M	Buy	480,000 +200,000	+71%	+$4.5M	0.02%	687
2025 Q4	$6.44M	Sell	280,000 -150,000	-35%	-$4.93M	0.01%	732
2025 Q3	$12.9M	Sell	430,000 -1,099,474	-72%	-$33M	0.02%	582
2025 Q2	$55.6M	Sell	1,529,474 -619,526	-29%	-$22.3M	0.09%	211
2025 Q1	$77.8M	Buy	2,149,000 +965,919	+82%	+$40.2M	0.14%	138
2024 Q4	$49.8M	Sell	1,183,081 -342,660	-22%	-$17M	0.09%	222
2024 Q3	$84.8M	Buy	1,525,741 +400,741	+36%	+$20.4M	0.15%	136
2024 Q2	$46.2M	Buy	1,125,000 +975,000	+650%	+$41.6M	0.09%	231
2024 Q1	$7M	Sell	150,000 -875,000	-85%	-$41.3M	0.01%	660
2023 Q4	$49M	Buy	1,025,000 +935,000	+1,039%	+$36.2M	0.1%	213
2023 Q3	$3.21M	Sell	90,000 -17,600	-16%	-$697K	0.01%	710
2023 Q2	$4.96M	Sell	107,600 -14,400	-12%	-$668K	0.01%	671
2023 Q1	$4.89M	Sell	122,000 -18,000	-13%	-$772K	0.01%	709
2022 Q4	$6.49M	Sell	140,000 -15,062	-10%	-$592K	0.02%	719
2022 Q3	$6.42M	Sell	155,062 -524,938	-77%	-$27M	0.02%	745
2022 Q2	$40.6M	Sell	680,000 -20,000	-3%	-$1.23M	0.09%	233
2022 Q1	$50.8M	Hold	700,000	–	–	0.1%	210
2021 Q4	$58.9M	Buy	700,000 +80,000	+13%	+$6.51M	0.11%	192
2021 Q3	$55.9M	Buy	620,000 +360,000	+138%	+$32.5M	0.11%	197
2021 Q2	$24.8M	Buy	260,000 +75,000	+41%	+$7.81M	0.05%	385
2021 Q1	$21.1M	Buy	185,000 +19,500	+12%	+$2.65M	0.04%	433
2020 Q4	$22.9M	Buy	+165,500	New	+$19.6M	0.05%	387
2018 Q4	–	Sell	-44,476	Closed	-$3.4M	–	745
2018 Q3	$3.4M	Sell	44,476 -283,024	-86%	-$23M	0.01%	659
2018 Q2	$25.2M	Sell	327,500 -161,703	-33%	-$10.4M	0.06%	353
2018 Q1	$24.9M	Buy	489,203 +381,703	+355%	+$19.2M	0.06%	348
2017 Q4	$4.99M	Sell	107,500 -81,000	-43%	-$3.97M	0.01%	626
2017 Q3	$10M	Sell	188,500 -279,000	-60%	-$16.5M	0.02%	559
2017 Q2	$29M	Buy	467,500 +327,000	+233%	+$19.7M	0.07%	339
2017 Q1	$9.52M	Sell	140,500 -488,000	-78%	-$37.2M	0.02%	546
2016 Q4	$44.2M	Sell	628,500 -50,000	-7%	-$3.55M	0.12%	220
2016 Q3	$48.1M	Buy	678,500 +40,000	+6%	+$2.55M	0.13%	214
2016 Q2	$31.2M	Buy	638,500 +155,000	+32%	+$10M	0.09%	276
2016 Q1	$30.6M	Buy	483,500 +150,000	+45%	+$9.82M	0.08%	271
2015 Q4	$37.4M	Sell	333,500 -105,000	-24%	-$10.5M	0.1%	245
2015 Q3	$42.2M	Sell	438,500 -186,500	-30%	-$21.4M	0.12%	227
2015 Q2	$64M	Sell	625,000 -325,000	-34%	-$25.2M	0.16%	178
2015 Q1	$59M	Sell	950,000 -116,826	-11%	-$6.49M	0.14%	199
2014 Q4	$46.8M	Buy	1,066,826 +16,826	+2%	+$771K	0.11%	246
2014 Q3	$59.4M	Sell	1,050,000 -706,968	-40%	-$35.6M	0.15%	190
2014 Q2	$78.9M	Sell	1,756,968 -83,815	-5%	-$3.45M	0.2%	141
2014 Q1	$90M	Buy	+1,840,783	New	+$94.8M	0.25%	124

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Adage Capital Partners's RARE Position: Q1 2026 in Review

Adage Capital Partners increased its Ultragenyx Pharmaceutical (RARE) stake by 71% in Q1 2026, buying an estimated $4.5M and bringing the position to 480,000 shares worth $10.1M. The position accounts for 0.02% of the portfolio, ranked #687.

Adage Capital Partners first reported a position in RARE in Q1 2014 and has held it in 41 quarters since. The position peaked at $90M in Q1 2014. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Adage Capital Partners held 480,000 shares of Ultragenyx Pharmaceutical worth $10.1M as of Q1 2026.
Adage Capital Partners bought 200,000 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $4.5M.
Ultragenyx Pharmaceutical made up 0.02% of Adage Capital Partners's portfolio in Q1 2026, its #687 holding.
Adage Capital Partners first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 41 quarters since.
Adage Capital Partners's Ultragenyx Pharmaceutical position peaked at $90M in Q1 2014.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.